Aligos Therapeutics, Inc. income statement

In fiscal 2025, Aligos Therapeutics, Inc. reported revenue of $2.2m, down 39.5% on the year before, operating income of −$88.0m (a -4024.9% margin) and net income of −$24.2m, or −$2.45 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Aligos Therapeutics, Inc.: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	0	0	6	4	2	4
Research and development	80	104	85	73	70	69	88
General and administrative	18	29	26	31	23	21	22
Operating income	−98	−128	−98	−88	−89	−88	−79
Net interest income	—	—	2	4	2	2	1
Income before tax	−108	−128	−96	−87	−131	−24	−73
Income tax	0	0	0	1	0	0	3
Net income	−109	−128	−96	−88	−131	−24	−76
Diluted EPS	−$67.94	−$3.22	−$2.25	−$34.20	−$20.94	−$2.45	−$7.35
Diluted shares (average)	2m	2m	2m	3m	6m	10m	10m
EBITDA	−95	−125	−95	−87	−88	−87	−78

US$ millions unless shown otherwise. Fiscal quarters.

Aligos Therapeutics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	1	1	0	1	1	0	3	0
Research and development	17	16	15	14	24	17	23	24
General and administrative	5	5	5	6	5	5	6	6
Operating income	−20	−21	−19	−19	−28	−22	−27	−2
Net interest income	1	0	1	0	0	1	0	0
Income before tax	−19	−82	43	−16	−31	−20	−23	1
Income tax	0	0	0	0	0	0	0	3
Net income	−19	−82	43	−16	−32	−20	−23	−2
Diluted EPS	−$3.07	−$13.10	−$2.11	−$1.53	−$3.04	−$2.01	−$2.21	−$0.14
EBITDA	−20	−20	−19	−18	−28	−22	−27	−2

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ALGS vs DYAI ALGS vs DBVT ALGS vs CAMP ALGS vs XBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aligos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aligos Therapeutics, Inc.